COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade
Kyle Hansen, Sandeep Kumar, Kathryn Logronio, Sarah Whelan, Samir Qurashi, Hsin‐Yuan Cheng, Andrew Drake, Margaret L. Tang, Patrick D. Wall, David Bernados, Ling Leung, Eran Ophir, Zoya Alteber, Gady Cojocaru, Moran Galperin, Masha Frenkel, Mark A. White, John Hunter, Spencer C. Liang, Maya F. Kotturi
Topics & Concepts
TIGITCancer researchAntibodyImmune systemBlockadeCD8T cellMonoclonal antibodyDownregulation and upregulationImmune checkpointImmunotherapyIn vivoImmunologyMedicineBiologyReceptorInternal medicineBiochemistryGeneBiotechnologyCAR-T cell therapy researchT-cell and B-cell ImmunologyImmune Cell Function and Interaction